缓释渗透增敏化疗加放疗综合治疗食管癌50例

Radiosensitizing effect of extended-release chemotherapy combined with radiotherapy in treatment of esophageal cancer:an analysis of 50 cases

目的:探讨缓释渗透增敏化疗加放疗综合治疗食管癌的疗效.方法:采取食管缓释渗疗器局部缓释渗疗同时配合X线常规放疗50例食管癌,另50例行单纯常规分割X线外照射作为同期对照研究;观察近期疗效及1,3,5a生存率.结果:缓释渗透治疗组与单纯放疗组的完全缓解(CR),部分缓解(PR),CR+PR,无变化(NC),肿瘤进展(PD)分别为:55.1%,10%;40.8%,60%;95.9%,70%;0,20%;4.8%,10%.缓释渗透治疗组的CR,CR+PR,PR与单纯放疗组相比有显著性差异(P<0.01或P<0.05).生存情况:缓释渗透治疗组与单纯放疗组1a生存率为73.46%,52%(P<0.05);3a生存率为40.8%,28%(P>0.05);5a生存率为16.3%,0(P<0.005).结论:食管缓释渗疗器局部缓释渗疗配合常规分割放疗综合治疗食管癌,有显著的近期疗效;同时改善了患者的生存率.

AIM： To evaluate the effect of extended-release chemotherapy combined with conventional fractionation radiotherapy in treatment of esophageal cancer. METHODS： A total of 100 patients with esophageal carcinoma were randomly divided into experiment group （n = 50） and control group （n = 50）. The experiment group received extendedrelease chemotherapy combined with conventional fractionation radiotherapy （X-ray external irradiation）, while the control group was treated only with conventional fractionation radiotherapy. The recent efficacy as well as the 1-, 3-, and 5-year survival rates was observed. RESULTS： The rates for complete remission （CR）, partial remission （PR）, CR plus PR, nonchanges （NC）, and disease progression were 55.1%, 40.8%, 95.92%, 0, and 4.08% in the experiment group and 10%, 60%, 70%, 20%, and 10% in the control group, respectively; CR, CR＋PR, and PR were significantly different between the two groups （P 〈 0.05 or P 〈 0.01）. The 1-, 3-, and 5-year survival rates were 73.46%, 40.8% and 16.3% in the experiment group and 52%, 28% and 0 in the control group; the 1- and 5-year survival rates were markedly different between the two groups （P 〈 0.05, P 〈 0.005）. CONCLUSION： The recent efficacy and survival rates of extended-release chemotherapy combined with conventional fractionation radiotherapy are superior to conventional fractionation radiotherapy alone in the treatment of esophageal cancer.